Alpha-2 agonist-induced memory impairment is mediated by the alpha-2A-adrenoceptor subtype

Behavioural Brain Research

Volumn 153, Issue 2, 2004, Pages 409-417

  Galeotti, Nicoletta ^a   Bartolini, Alessandro ^a   Ghelardini, Carla ^a  

^a I 50139 ^*  (Italy)

Author keywords

2 Adrenoceptor agonists; 2A Adrenoceptor subtype; Amnesia; Clonidine; Guanabenz; Passive avoidance

Indexed keywords

2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; 2 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 4,4 DIMETHYL 1,3(2H,4H) ISOQUINOLINEDIONE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2A ADRENERGIC RECEPTOR; CLONIDINE; GUANABENZ; PRAZOSIN; RECEPTOR SUBTYPE; YOHIMBINE;

AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; DRUG EFFECT; MALE; MEMORY DISORDER; MOTOR COORDINATION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; TASK PERFORMANCE; TREATMENT OUTCOME;

ANIMALS; AVOIDANCE LEARNING; BRAIN; CLONIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; FEAR; GUANABENZ; IMIDAZOLES; INDOLES; INJECTIONS, INTRAPERITONEAL; MALE; MENTAL RECALL; MICE; MOTOR ACTIVITY; MOTOR SKILLS; REACTION TIME; RECEPTORS, ADRENERGIC, ALPHA-2; YOHIMBINE;

EID: 3242666903     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2003.12.016     Document Type: Article

References (49)

1. Aoki C., Go C.G., Venkatesan C., Kurose H. Perikaryal and synaptic localization of alpha 2A-adrenergic receptor-like immunoreactivity. Brain Res. 650:1994;181-204
2. Arnsten A.F.T., Contant T.A. Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacology. 108:1992;159-169
3. 2-Adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged human primates. Science. 230:1985;1273-1276
4. Arnsten A.F.T., Jentesch J.D. The alpha-1 adrenergic agonist, cirazoline, impairs spatial working memory performance in aged monkeys. Pharmacol. Biochem. Behav. 58:1997;55-59
5. Arnsten A.F.T., Mathew R., Ubriani R., Taylor J.R., Li B.-M. Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol. Psychiatry. 45:1999;26-31
6. Birnbaum S.G., Podell D.M., Arnsten A.F.T. Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol. Biochem. Behav. 67:2000;397-403
7. Björklund M., Sirviö J., Riekkinen M., Sallinen J., Scheinin M., Riekkinen P. Jr. Overexpression of alpha 2C-adrenoceptors impairs water maze navigation. Neuroscience. 95:2000;481-487
8. 3H ]idazoxan in rat brain J Pharmacol Exp Ther. 241:1987;1092-1098
9. Brozoski T., Brown R.M., Rosvold H.E., Goldman P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkeys. Science. 205:1979;929-931
10. Bylund D.B. Heterogenity of α-2 adrenergic receptors. Pharmacol. Biochem. Behav. 22:1985;835-843
11. Cai J.-X., Ma Y., Xu L., Hu X. Reserpine impairs spatial working memory performance in monkeys: reversal by the α-2-adrenergic agonist clonidine. Brain Res. 614:1993;191-196
12. Cohen D.J., Detlor J., Young J.G., Shaywitz B.A. Clonidine ameliorates gille de la tourette syndrome. Arch Gentile Psychiatry. 37:1980;1350-1357
13. Coyle MJ. A cholinergic hypothesis for Alzheimer's disease. In: Meyer L, Nordeberg GH, editors. Learning and memory molecular bases. London: Pergamon Press; 1995. p. 11-32.
14. Fields R.B., Van Kammen D.P., Peters J.L., Rosen J., Van Kammen W.B., Nugent A., et al. Clonidine improves memory function in schizophrenia independently from change in psychosis. Schiz. Res. 1:1988;417-423
15. Franowicz J.S., Kessler L.E., Borja C.M., Kobilka B.K., Limbird L.E., Arnsten A.F. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J. Neurosci. 22:2002;8771-8777
16. Genkova-Papazova M., Lazarova-Bakarova M. Influence of nootropic drugs on the memory-impairing effect of diethyldithiocarbamate and clonidine in "step-down" passive avoidance in albino rats. Acta. Physiol. Pharmacol. Bulg. 14:1988;36-41
17. Genkova-Papazova M., Petkova-Petkova B., Lazarova-Bakarova M., Boyanova E., Staneva-Stoytcheva D. Effects of flunarizine and nitrendipine on electroconvulsive shock- and clonidine-induced amnesia. Pharmacol. Biochem. Behav. 56:1997;583-587
18. Gouliaev A.H., Senning A. Piracetam and other structurally related nootropics. Brain Res. Rev. 19:1994;180-222
19. Hall J.E., Uhrich T.D., Barney J.A., Arain S.R., Ebert T.J. Sedative, amnestic, and analgesic properties of small-dose dexmetedomidine infusions. Anesth. Analg. 90:2000;699-705
20. Hall J.E., Uhrich T.D., Ebert T.J. Sedative, analgesic and cognitive effects of clonidine infusions in humans. Br. J. Anasth. 86:2001;5-11
21. Hardy M.-C., Lecrubier Y., Widlocher D. Efficacy of clonidine in 24 patients with acute mania. Am. J. Psychiatry. 143:1986;1450-1453
22. Hawkins M., Monti J.M. Effects of pretreatment with 6-hydroxydopamine or noradrenergic receptor blockers on the clonidine-induced disruption of conditioned avoidance responding. Eur. J. Pharmacol. 58:1979;53-58
23. 2-adrenoceptors and acute stress. Behav. Pharmacol. 14:2003;41-48
24. Horrigan J.P., Barnhill L.J. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J. Child Adolesc. Psychopharmacol. 5:1995;215-223
25. Hunt R.D., Mindera R.B., Cohen D.J. Clonidine beneficts children with ADD and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J. Am. Acad. Child Psychiatry. 24:1985;617-629
26. Jackson W.J., Buccafusco J.J. Clonidine enhances delayed matching-to-sample performance by young and aged monkeys. Pharmacol. Biochem. Behav. 39:1991;79-84
27. Jäkälä P., Riekkinen M., Sirvio J., Koivisto E., Kejonen K., Vanhanen M., et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology. 20:1999;460-470
28. Jarvik M.E., Kopp R. An improved one-trial passive avoidance learning situation. Psychol. Rep. 21:1967;221-224
29. Kable J.W., Murrin L.C., Bylund D.B. In vivo gene modification elucidates subtype-specific functions of the alpha-2 adrenergic receptors. J. Pharmacol. Exp. Ther. 293:2000;1-7
30. Khan Z.P., Ferguson C.N., Jones R.M. α-2 and imidazoline receptor agonists: their pharmacological and therapeutical role. Anaesthesia. 54:1999;146-165
31. Kobilka B.K., Matsui H., Kobilka T.S., Yang-Feng T.L., Francke U., Caron M.G., et al. Cloning, sequenceing, and expression of the gene coding for the human platelet α-2 adrenergic receptor. Science. 238:1987;650-656
32. Kostowski W., Plaznik A., Pucilowski A. Effect of chronic clonidine treatment and lesion of the locus coeruleus on the conditioned avoidance behavior in rats. Pl. J. Pharmacol. Pharm. 32:1980;305-312
33. Li B.-M., Mao Z.-M., Wang M., Mei Z.-T. Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys. Neuropsychopharmacology. 21:1999;601-610
34. Lomasney J.W., Lorenz W., Allen L.F., King K., Regan J.W., Yang-Feng T.L., et al. Expansion of the a-2-adrenergic receptor family: cloning and characterization of a human α-2-adrenergic receptor subtype, the gene for which is located on chromosome 2. Proc. Natl. Acad. Sci. USA. 87:1990;5094-5098
35. Mair R.G., McEntee W.J. Cognitive enhancement in Korsakoff's psychosis by clonidine: a comparison with L-DOPA and ephedrine. Psychopharmacology. 88:1986;374-380
36. 2-adrenoceptors in the central nervous system. J. Physiol. Pharmacol. 46:1995;241-258
37. 2-adrenoceptor-subtype function. Trends Pharmacol. Sci. 18:1997;211-219
38. Rama P., Linnanskoski I., Tanila H., Pertovaara A., Carlson S. Metedotimine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Pharmacol. Biochem. Behav. 55:1996;415-422
39. Regan J.W., Kobilka T.S., Yang-Feng T.L., Caron M.G., Lefkowitz R.J., Kobilka B.K. Cloning and expression of human kidney cDNA for and a-2-adrenergic receptor subtype. Proc. Natl. Acad. Sci. USA. 85:1988;6301-6305
40. alpha-2A adrenergic receptor and other populations of alpha-2 adrenergic subtypes J. Pharmacol. Exp. Ther. 270:1994;946-957
41. Riekkinen M., Jäkälä P., Kejonen K., Riekkinen P. Jr. The alpha-2 agonist, clonidine, improves spatial working memory performance in Parkinson's disease. Neuroscience. 92:1999;983-989
42. Riekkinen M., Laakso M.P., Jäkälä P. Clonidine impairs sustained attention and memory in Alzheimer's disease. Neuroscience. 92:1999;975-982
43. Scahill L., Chappell P.B., Kim Y.S., Schultz R.T., Katsovich L., Shepherd E., et al. Guanfacine in the treatment of children with tic disorders and ADHD: a placebo-controlled study. Am. J. Psychiatry. 158:2001;1067-1074
44. Schneider J.S., Kovelowski C.J. Chronic exposure to low doses of MPTP, I: Cognitive deficits in motor asymptomatic monkeys. Brain Res. 519:1990;122-128
45. Tanila H., Rama P., Carlson S. The effects of prefrontal intracortical microinjections of an α-2 agonist α-2 antagonist and lidocaine on the delayed alternation performance of aged rats. Brain Res. Bull. 40:1996;117-119
46. 2C-adrenoceptor gene. Eur. J. Neurosci. 11:1999;599-603
47. 2-adrenoceptor Br. J. Pharmacol. 106:1992;986-995
48. van Zwieten P.A. Centrally acting antihypertensive drugs. Present and future. Clin. Exp. Hypertens. 21:1999;859-873
49. Vaught J., Pelley K., Costa L.G., Sether P., Enna S.J. A comparison of the antinociceptive responses to GABA-receptor agonists THIP and baclofen. Neuropharmacology. 24:1985;211-216